ORGSOrgenesis Inc.

Nasdaq orgenesis.com


$ 0.60 $ -0.01 (-2.12 %)    

Monday, 16-Sep-2024 15:59:43 EDT
QQQ $ 476.45 $ 0.48 (0.1 %)
DIA $ 417.33 $ 2.44 (0.59 %)
SPY $ 562.48 $ 0.83 (0.15 %)
TLT $ 101.29 $ 0.92 (0.92 %)
GLD $ 238.61 $ -0.02 (-0.01 %)
$ 0.595
$ 0.55 x 121
-- x --
-- - --
$ 0.25 - $ 1.08
155,655
na
27.92M
$ 1.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-20-2024 03-31-2024 10-Q
3 04-15-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-10-2023 03-31-2023 10-Q
7 03-22-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-23-2022 03-31-2022 10-Q
11 03-30-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 03-09-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-08-2020 03-31-2020 10-Q
19 03-09-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 02-13-2019 11-30-2018 10-K
24 10-12-2018 08-31-2018 10-Q
25 07-17-2018 05-31-2018 10-Q
26 04-16-2018 02-28-2018 10-Q
27 02-28-2018 12-31-2017 10-K
28 10-16-2017 08-31-2017 10-Q
29 07-24-2017 05-31-2017 10-Q
30 04-19-2017 02-28-2017 10-Q
31 02-28-2017 11-30-2016 10-K
32 10-14-2016 08-31-2016 10-Q
33 07-15-2016 05-31-2016 10-Q
34 04-14-2016 02-29-2016 10-Q
35 02-29-2016 11-30-2015 10-K
36 10-15-2015 08-31-2015 10-Q
37 07-15-2015 05-31-2015 10-Q
38 04-14-2015 02-28-2015 10-Q
39 02-19-2015 11-30-2014 10-K
40 10-15-2014 08-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 orgenesis-announces-results-from-a-real-world-study-of-org-101-car-t-therapy-in-patients-with-cd19-acute-lymphoblastic-leukemia-top-line-efficacy-and-safety-data-from-the-study-had-a-complete-response-of-82-in-adult-patients-and-93-in-pediatric-patients

Orgenesis' CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with th...

 orgenesis-announces-strategic-partnership-with-harley-street-healthcare-group-to-launch-a-longevity--wellness-initiative-globally-orgenesis-and-hshg-will-establish-a-jv-with-orgenesis-owning-49-and-hshg-owning-51-of-the-entity-hshg-has-agreed-to-invest-up-to-10m-over-3-years-into-orgenesis-and-the-joint-venture

Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the ful...

 correction-orgenesis-q2-eps-loss-of-023-up-from-076-yoy-sales-24600k-up-from-11300k-yoy

Orgenesis (NASDAQ:ORGS) reported quarterly losses of $(0.23) per share. This is a 69.74 percent increase over losses of $(0.76)...

 orgenesis-entered-purchase-deal-with-theracell-for-purchase-of-50-outstanding-ownership-rights--equity-interests-in-theracell-laboratories-ike-pursuant-to-deal-for-purchase-of-assets-co-to-pay-theracell-13m

- SEC Filing

 orgenesis-q1-eps-029-down-from-017-yoy-sales-14100k-miss-1200m-estimate

Orgenesis (NASDAQ:ORGS) reported quarterly losses of $(0.29) per share. This is a 270.59 percent decrease over earnings of $0.1...

 orgenesis-inc-files-for-mixed-shelf-of-up-to-100m--sec-filing

- SEC Filing

 germfree-and-orgenesis-announce-asset-purchase-and-strategic-partnership-intended-to-revolutionize-cell-and-gene-therapy-through-decentralized-production-and-global-accessibility

Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (NASDAQ:ORGS), a global lead...

 why-stryve-foods-shares-are-trading-lower-by-around-25-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.

 why-nuvve-holding-shares-are-trading-lower-by-around-30-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expect...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION